04.10.2016 07:50:01

MdxHealth: SouthGenetics To Distribute SelectMDx In Central/South America

(RTTNews) - MDxHealth SA (MXDHF.PK), a healthcare provider of actionable epigenetic information to personalize the diagnosis and treatment of urologic cancers, announced Tuesday that it has signed a distribution agreement for their SelectMDx for Prostate Cancer assay in select countries in Central and South America with SouthGenetics Inc.

Under the deal terms, SouthGenetics, an Uruguay-based biotechnology distribution company, will have the rights to distribute SelectMDx assay within the following countries: Argentina, Bolivia, Chili, Columbia, Ecuador, Mexico, Peru, Dominican Republic, Panama, Paraguay, Uruguay, and Venezuela.

SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. It helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection.

Eintrag hinzufügen

Aktien Top Flop

Swiss Life Hldg 342.50
6.30 %
The Swatch Grp 190.50
5.05 %
Swiss Re 66.20
4.95 %
UBS Group 10.04
4.12 %
CS Group 8.44
3.59 %
Novartis 82.28
-1.00 %
Alcon 60.06
-1.05 %
Nestle 102.58
-1.19 %
Roche Hldg G 344.25
-1.36 %
Lonza Grp 485.80
-3.00 %
Ruhige Woche bahnt sich an | BX Swiss TV

Finanzen.net News

pagehit